15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Abeona Therapeutics Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $20.00 to $20.00, so the covering firms are broadly aligned. The average target of $20.00 sits 231% above the current $6.04. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees revenue growth near 1026% this year and 106% next, consensus EPS building from about $-0.11 next quarter toward $0.29 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Abeona Therapeutics Inc.
As of Jul, 2 of 2 firms rate ABEO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ABEO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.11
Range $-0.20 – $-0.01 · 3 analysts · +2% YoY
Next period, 3 analysts expect Abeona Therapeutics Inc to earn $-0.11 a share (range $-0.20 – $-0.01), versus $-0.11 a year earlier. Full-year consensus is $-0.68, growing to $0.29 the year after.
REVENUE · NEXT QUARTER
$20.0M
Range $14.8M – $27.1M · 3 analysts · +0% YoY
Revenue is expected to reach $20.0M (range $14.8M – $27.1M), +0.0% year-over-year. Full-year consensus is $65.5M, rising to $134.9M next year.
Top analysts covering Abeona Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ABEO.
#1
Kristen Kluska
Cantor Fitzgerald · Rank #162
Buy
$28.00+364.0% to target
Overall win rate
38%
+ Follow
#2
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Buy
$15.00+148.6% to target
Overall win rate
34%
+ Follow
#3
Francois Brisebois
Oppenheimer · Rank #186
Buy
$16.00+165.1% to target
Overall win rate
40%
+ Follow
#4
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$20.00+231.4% to target
Overall win rate
37%
+ Follow
#5
Andreas Argyrides
Oppenheimer
Buy
$20.00+231.4% to target
Coverage
—
+ Follow
ABEO stock forecast FAQ
What is ABEO's average 12-month price target?+
The 2 analysts with a live target average $20.00 for Abeona Therapeutics Inc over the next 12 months, ranging from a $20.00 high to a $20.00 low.
Is ABEO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover ABEO?+
2 analysts have an active rating on Abeona Therapeutics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering ABEO?+
Among analysts who currently cover ABEO, Kristen Kluska of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #162). Their current call is Buy with a $28.00 target.
What is Abeona Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.11 per share (range $-0.20 – $-0.01) across 3 analysts. Full-year EPS is projected at $-0.68, rising to $0.29 the following year.
How much revenue is Abeona Therapeutics Inc expected to report next quarter?+
Consensus revenue is $20.0M (range $14.8M – $27.1M). Full-year revenue is projected at $65.5M, growing to $134.9M next year.
Have analysts been upgrading or downgrading ABEO lately?+
As of Jul, 2 of 2 firms rate ABEO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ABEO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
